A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors

NCT06710847 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

14

Enrollment

INDUSTRY

Sponsor class

Conditions

Neoplasms, Colorectal
Solid Tumor
Colon Cancer
Rectal Cancer
Endometrial Cancer

Interventions

DRUG: GSK4418959
BIOLOGICAL: PD-1 inhibitor

Sponsor

GlaxoSmithKline

Collaborators

[object Object]